Fluence Named a Forbes 2024 Most Successful Mid-Cap Company 18-01-2024, 21:05

Sportradar Deepens Official Partnership with NBA with Launch of Innovative, Value-Add Fan Engagement Solutions 22-10-2024, 20:00

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability 3-09-2024, 19:00